Affiliation:
1. Genetics of Ashrafi Esfahani University
2. Provincial General Office of Technical and Vocational Education zist fanavari novin
3. University of Pavia
Abstract
Abstract
Introduction: Multiple sclerosis (MS) is one of the three leading neurodegenerative diseases worldwide. Genes expression profiles studies play important role in recognition and prevention of disease. Considering the inherent ability of biomarkers to diagnose and prognosis the occurrence of a disease, with the aim of gene therapy and changing gene expression, it can be helped to treat it. In this study, by examining the gene interaction and expression of non-coding gene in patients with multiple sclerosis, using bioinformatics analyzes and laboratory research, to find the gene expression pattern and the interaction of potential biomarkers of this disease for It was tried to find suitable treatment targets.
Materials and methods: First, by using microarray data analysis of GEO database, the expression status of Lnc RNA A2M-AS1 gene was investigated in patients with MS. Then lncRNA-mRNA interaction analysis was performed in the lncRRisearch and ENCORI database. After sample collection, the total RNA extracted using the RNA extraction kit from 20 patient samples and 20 healthy samples was synthesized into cDNA with the synthesis kit. In the following, two pairs of forward and reverse primers were designed for A2M-AS1 gene, and finally, the expression level was measured by Real Time-PCR technique.
Result: Based on bioinformatic and laboratory analysis, the expression of A2M-AS1 gene in MS samples showed a significant decrease in expression compared to healthy samples. Also, based on the ROC analysis, lncRNA A2M-AS1 can be introduced as an acceptable diagnostic biomarker to distinguish MS samples from healthy samples.
Conclusion: lncRNA A2M-AS1 by reducing its expression as an acceptable diagnostic biomarker can increases the risk of developing MS.
Publisher
Research Square Platform LLC
Reference23 articles.
1. Erkkinen MG, Kim MO, Geschwind MD. Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. Cold Spring Harb Perspect Biol [Internet]. 2018 Apr 1 [cited 2023 May 22];10(4):a033118. Available from: http://cshperspectives.cshlp.org/content/10/4/a033118.full.
2. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol [Internet]. 2007 Apr 1 [cited 2023 May 22];61(4):288–99. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ana.21117.
3. Nakahara J, Maeda M, Aiso S, Suzuki N. Current concepts in multiple sclerosis: Autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol [Internet]. 2012 Feb 22 [cited 2023 May 22];42(1):26–34. Available from: https://link.springer.com/article/10.1007/s12016-011-8287-6.
4. Multiple sclerosis;Compston A;The Lancet,2008
5. Ascherio A, Munger KL, White R, Köchert K, Simon KC, Polman CH et al. Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. JAMA Neurol [Internet]. 2014 Mar 1 [cited 2023 May 23];71(3):306–14. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/1815002.